All posts by: Michael Zand

Norwegian Biotech Announces Positive Phase I Results for T cell-Stimulating Vaccine
Labiotech.eu (blog)
PCI Biotech’s T cell-stimulating vaccine enhances the cellular immune response, supporting it as a candidate for use alongside cancer vaccines. PCI Biotech, based in Oslo, Norway, has seen … photochemical internalization (PCI) technology. A …

and more »

FDA Extends Holds in Immunotherapy Trials in Blood Cancers
Medscape
Because of safety concerns, the US Food and Drug Administration has placed full or partial holds on clinical trials of three immunotherapies — pembrolizumab (Keytruda, Merck), nivolumab (Opdivo, BMS), and durvalumab (Imfinzi, AstraZeneca) — that are …

Immunotherapy Also Good for Early-Stage Cancers
Newsmax
Cancer doctors are widening the net for immunotherapy, a hot new class of drugs that enlist the body’s defenses in the fight against tumors. The latest research shared with 23,000 experts at Europe’s top oncology meeting shows how medicines that have …
Cancer Immunotherapy Useful at Initial StagesThe Global Health News (press release) (blog)
Cancer mutation gains ground as test for immunotherapy drugsSaudi Gazette
ESMO 2017 round up: BMS and AZ bounce backpharmaphorum

all 8 news articles »

Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type …
Markets Insider
The initiation of this natural history study brings us one step closer to our goal of making a CRISPR-based medicine available to people with significant vision loss caused by LCA10,” said Gerry Cox, M.D., Ph.D., Chief Medical Officer, Editas Medicine.

and more »

Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type …
Markets Insider
The initiation of this natural history study brings us one step closer to our goal of making a CRISPR-based medicine available to people with significant vision loss caused by LCA10,” said Gerry Cox, M.D., Ph.D., Chief Medical Officer, Editas Medicine.

and more »

Scientists Identify New Immunotherapy Target for Pediatric Cancers
Genetic Engineering & Biotechnology News (press release)
Scientists in the U.S. and Canada have identified a key immunotherapy target for high-risk neuroblastoma and other childhood cancers, and developed an antibody-drug conjugate (ADC) targeting the cell surface co-receptor, glypican 2 (GLP2), which …
Cell surface protein may offer target in treating childhood cancersDrug Target Review

all 2 news articles »